Use of blood products and factor concentrates for coagulation therapy.
Therapy of coagulation disorders has evolved from early use of fresh whole blood and plasma, to sophisticated recombinant factor concentrates. Although current testing protocols and viral inactivation methods ensure that transfusion of components is safer than ever, the potential for new threats continually exists, e.g., West Nile virus. Effective therapy depends on treating the specific deficiency with the safest and most appropriate replacement product, in the proper dose.
Fritsma
Margaret G
MG
School of Health Related Professions, Clinical Laboratory Sciences, University of Alabama at Birmingham, 1705 University Boulevard, RMSB Room 450, Birmingham, AL 35294-1212, USA. fritsmam@uab.edu
D001778:Blood Coagulation Disorders / Q000628:therapy*; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D016913:Blood Component Transfusion / Q000379:methods*; D005169:Factor VIII / Q000627:therapeutic use; D005340:Fibrinogen / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy; D006801:Humans; D010949:Plasma; D017713:Platelet Transfusion
D001779:Blood Coagulation Factors; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen